Date: 2016-02-16
Type of information: Collaboration agreement
Compound:
Company: Merck KGaA (Germany) Weizmann Institute (Israel)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration R&D
Action mechanism:
Disease:
Details: * On February 16, 2016, Merck KGaA extended the partnership with Weizmann Institute of Science, Rehovot, Israel, of by signing a new framework agreement, building on a successful innovation partnership of almost four decades. The new framework agreement on research collaboration and licensing was signed by Stefan Oschmann, Deputy CEO and Vice Chairman of the Executive Board of Merck, Belén Garijo, Member of the Executive Board of Merck and CEO Healthcare, Prof. Mudi Sheves, Vice President of Technology Transfer of the Weizmann Institute, and Amir Naiberg, CEO of Yeda, the commercial arm of the Weizmann Institute, at Weizmann’s site in Rehovot. It will span the next three years, with an option for multiple successive extensions of two years each. Merck’s ties in research and development collaboration with the Weizmann Institute go back as far as 1978. Merck’s top selling drug Rebif® for the treatment of multiple sclerosis has intellectual roots in Israel’s Weizmann Institute, as has Merck’s oncology drug Erbitux®.
“We have focused our healthcare research activities on the highly promising fields of immuno-oncology, immunology and oncology as we’re striving to deliver new solutions to respond to unmet medical needs,” Oschmann said.
Financial terms: As part of the new framework agreement Merck will fund each of the two research areas with up to € 1 million per year over the three-year period initially.
Latest news:
